Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27374789.
- Also identified by DOI 10.1016/j.stem.2016.06.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.
Medical subject headings
- Drug Industry
- Marketing
- Stem Cells